0001209191-21-054331.txt : 20210901
0001209191-21-054331.hdr.sgml : 20210901
20210901202127
ACCESSION NUMBER: 0001209191-21-054331
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210830
FILED AS OF DATE: 20210901
DATE AS OF CHANGE: 20210901
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEONARD JOHN M
CENTRAL INDEX KEY: 0001563584
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 211231491
MAIL ADDRESS:
STREET 1: C/O INTELLIA THERAPEUTICS INC
STREET 2: 40 ERIE STREET, SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER NAME:
FORMER CONFORMED NAME: LEONARD JOHN M.
DATE OF NAME CHANGE: 20121204
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-30
0
0001652130
Intellia Therapeutics, Inc.
NTLA
0001563584
LEONARD JOHN M
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
CAMBRIDGE
MA
02139
1
1
0
0
President and CEO
Common Stock
2021-08-30
4
M
0
11637
13.40
A
730942
D
Common Stock
2021-08-30
4
M
0
27167
14.58
A
758109
D
Common Stock
2021-08-30
4
S
0
2055
152.81
D
756054
D
Common Stock
2021-08-30
4
S
0
2334
153.66
D
753720
D
Common Stock
2021-08-30
4
S
0
7428
154.98
D
746292
D
Common Stock
2021-08-30
4
S
0
15567
155.70
D
730725
D
Common Stock
2021-08-30
4
S
0
4758
156.96
D
725967
D
Common Stock
2021-08-30
4
S
0
3123
157.75
D
722844
D
Common Stock
2021-08-30
4
S
0
2598
159.18
D
720246
D
Common Stock
2021-08-30
4
S
0
725
159.98
D
719521
D
Common Stock
2021-08-30
4
S
0
216
160.69
D
719305
D
Common Stock
2021-08-31
4
M
0
37833
14.58
A
757138
D
Common Stock
2021-08-31
4
S
0
37833
155.00
D
719305
D
Common Stock
2021-09-01
4
M
0
28750
23.46
A
748055
D
Common Stock
2021-09-01
4
M
0
15985
18.30
A
764040
D
Common Stock
2021-09-01
4
S
0
44735
170.00
D
719305
D
Common Stock
58415
I
By Trust
Stock Option (right to buy)
13.40
2021-08-30
4
M
0
11637
0.00
D
2030-03-01
Common Stock
11637
212501
D
Stock Option (right to buy)
14.58
2021-08-30
4
M
0
27167
0.00
D
2028-12-17
Common Stock
27167
127833
D
Stock Option (right to buy)
14.58
2021-08-31
4
M
0
37833
0.00
D
2028-12-17
Common Stock
37833
90000
D
Stock Option (right to buy)
23.46
2021-09-01
4
M
0
28750
0.00
D
2028-03-20
Common Stock
28750
0
D
Stock Option (right to buy)
18.30
2021-09-01
4
M
0
15985
0.00
D
2027-12-11
Common Stock
15985
11515
D
The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.21 to $153.165, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.22 to $154.13, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.31 to $155.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.31 to $156.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.31 to $157.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.395 to $158.21, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.49 to $159.465, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.56 to $160.40, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.62 to $160.745, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
Shares held by the John M. Leonard 2015 Irrevocable Trust.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 30, 2021.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 160,000 shares as of August 30, 2021.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 31, 2020.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 66,458 shares as of September 1, 2021.
/s/James Basta Attorney-In-Fact
2021-09-01